Current Therapy of Multiple Myeloma

この論文にアクセスする

この論文をさがす

著者

抄録

Not all patients who fulfill the minimal criteria for the diagnosis of multiple myeloma should be treated. If a patient is younger than 70 years, autologous peripheral blood stem cell transplantation should be seriously considered. Major challenges for stem cell transplantation are: 1) the inability to eradicate multiple myeloma from the patient, and 2) removal of myeloma cells and their precursors from the reinfused stem cells. Allogeneic transplantation cannot be recommended at present because of the excessive mortality. Nonmyeloablative approaches are promising. There is no evidence that combinations of alkylating agents are superior to melphalan and prednisone. The use of thalidomide and intermittently administered prednisone for maintenance is being explored. New agents include the immunomodulatory drugs, inhibitors of the ubiquitin proteasone pathway such as PS-341, antiangiogenesis drugs including 2-methoxy-estradiol, and farnesyl transferase inhibitors. Management of skeletal complications, hypercalcemia, anemia, infection, spinal cord compression, and renal insufficiency is discussed.<br>(Internal Medicine 41: 175-180, 2002)

収録刊行物

  • Internal medicine

    Internal medicine 41(3), 175-180, 2002-03

    The Japanese Society of Internal Medicine

参考文献:  53件中 1-53件 を表示

被引用文献:  2件中 1-2件 を表示

各種コード

  • NII論文ID(NAID)
    10008034316
  • NII書誌ID(NCID)
    AA10827774
  • 本文言語コード
    ENG
  • 資料種別
    REV
  • ISSN
    09182918
  • NDL 記事登録ID
    6262741
  • NDL 雑誌分類
    ZS21(科学技術--医学--内科学)
  • NDL 請求記号
    Z53-M398
  • データ提供元
    CJP書誌  CJP引用  NDL  J-STAGE 
ページトップへ